Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
Date:9/9/2008

- Advances Achieved in All Clinical Programs, With Three Bavituximab Phase

II Cancer Trials Ongoing - - Updated Initial Data from Bavituximab Plus Docetaxel Phase II Breast Cancer Trial Shows at Least 9 of 14 Evaluable Patients Achieved a Partial

Tumor Response - - Company Begins Work under Contract with Defense Threat Reduction Agency

Potentially Worth Up to $44.4 Million -

TUSTIN, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced financial results for the first quarter of fiscal year (FY) 2009 ended July 31, 2008. The company reported a consolidated net loss of $5,086,000, or $0.02 per basic and diluted share, compared to a consolidated net loss of $4,656,000 or $0.02 per basic and diluted share for the same prior year period. The increased net loss primarily reflects increased investments in research and development as the company advanced its clinical programs for bavituximab and Cotara(R).

Total revenues for the current quarter were $1,517,000 compared to $1,625,000 for the comparable quarter last year and were primarily generated from services provided by Avid Bioservices, the company's wholly owned contract manufacturing subsidiary. Total revenues for the quarter also include the first government contract revenues generated by Peregrine's contract with the Defense Threat Reduction Agency (DTRA), potentially worth up to $44.4 million over a period of up to five years to evaluate bavituximab for the prevention or treatment of viral hemorrhagic fever infections.

Total costs and expenses increased to $6,677,000 in the first quarter of FY 2009 from $6,513,000 in the same prior year
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
2. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
3. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
4. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
5. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
6. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
7. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
8. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
9. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
10. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
(Date:7/10/2014)... 10, 2014  Franciscan St. Anthony Health-Crown ... for respiratory monitoring outside the operating room, ... in embracing state-of-the-art patient safety technology. ... breathing and can alert medical caregivers when ... amount of carbon dioxide the patient is ...
(Date:7/10/2014)... 10, 2014  Kainos Capital, a firm specializing in ... that it has acquired the Slim-Fast brand from Unilever. ... Terms of the transaction were not disclosed. ... business that markets ready-to-drink shakes, powders, bars and snacks ... and in the United Kingdom ...
(Date:7/10/2014)... 10, 2014 Research and Markets ( ... "International Photonic Integrated Circuit (Monolithic Integration, Hybrid ... report to their offering. ... of photonic integration traces its roots in the ... of photonic integration went unexplored and unfulfilled for ...
Breaking Biology Technology:Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Kainos Capital Acquires Slim-Fast From Unilever 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2
... 2003 , , MADISON, Wis. -- Forty-five ... the 2004 Technology Awards Banquet for receiving over $24.6 ... held in conjunction with the Wisconsin Entrepreneurs? Conference ... small business innovation research (SBIR) and advanced technology program ...
... MILWAUKEE Despite the encroachment of wireless technology, broadband ... popular with business and home users, according to Dan ... Warner Cable . , ,In his keynote address Wednesday ... what he sees as the future of broadband, mentioning ...
... has published the first-ever magazine about Wisconsins life ... research base, technology-transfer process, company creation, quality of ... joins Chicago, Wisconsin and Minneapolis-St. Paul. , ,The ... from Life Sciences: Wisconsin The Smart Choice, ...
Cached Biology Technology:Wisconsin technology companies awarded over $24 million in government funding 2Wisconsin technology companies awarded over $24 million in government funding 3Wisconsin technology companies awarded over $24 million in government funding 4Future of cable, wireless shown off at ITEC Milwaukee 2Future of cable, wireless shown off at ITEC Milwaukee 3Future of cable, wireless shown off at ITEC Milwaukee 4Life Sciences: Wisconsin- The Smart Choice 2Life Sciences: Wisconsin- The Smart Choice 3Life Sciences: Wisconsin- The Smart Choice 4Life Sciences: Wisconsin- The Smart Choice 5Life Sciences: Wisconsin- The Smart Choice 6Life Sciences: Wisconsin- The Smart Choice 7
(Date:7/11/2014)... study the proteins that let nerve cells send out ... upon a biological tactic that may offer a new ... safe and environmentally responsible way. , Their findingthat ... species and harmless for a closely related onesuggests that ... harming beneficial species like bees. A summary of the ...
(Date:7/10/2014)... Albuquerque, and other major cities in New Mexico, nearly ... municipal wastewater rather than precious potable water supplies. Across ... of all golf courses receive treated effluent. Reusing the ... Additionally, golf courses and homeowners alike fertilize their lawns ... is nitrate. A New Mexico State University turfgrass expert ...
(Date:7/10/2014)...  Pomerantz LLP has filed a class action ... "Company")(NYSE-MKT: PVCT) and certain of its officers.  The ... Middle District of Tennessee , ... consisting of all persons or entities who purchased ... 2013 and May 22, 2014, both dates inclusive ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3'Tailored' water -- the latest in lawn care 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... April issue of the Journal of the American ... eating plans; dietary quality among children; and relationships between ... Increased Risk of Eating Disorders , While vegetarians tend ... non-vegetarians to be overweight or obese, they may be ...
... the Richard King Trainee Award. This award was instituted last ... to encourage ABMG trainees in their careers and to foster ... year the editorial board will review all articles published in ... or corresponding author during that year. The manuscript felt to ...
... Being able to accurately predict how a given ... non-responsive tumors the burden of undergoing toxic and ultimately ... a patient,s cancer-causing genetic lesions are contributing to drug ... Researchers led by Professor Scott Lowe, Ph.D., ...
Cached Biology News:News from the April 2009 Journal of the American Dietetic Association 2Jonathan Berg, M.D., Ph.D. awarded Richard King Trainee Award for Best in Genetics in Medicine 2CSHL team develops mouse models of leukemia that predict response to chemotherapy 2CSHL team develops mouse models of leukemia that predict response to chemotherapy 3CSHL team develops mouse models of leukemia that predict response to chemotherapy 4
... workstation is the simplest, easiest-to-use system ever ... liquid handling capabilities,into their labs, or groups ... routine applications on a separate instrument. Plate-handling ... even when you have thousands of ...
... has generated hybridomas against a large ... initiation, you are provided with personalized ... cell lines developed by Covance remain ... typical hybridoma development project has four ...
... cDNA normalization is essential for ... using high-throughput approaches, such as EST ... Most normalization methods are not well ... cDNA. The Evrogen TRIMMER kit, though, ...
... ENGENISTM (Entire Gene/cDNA or Isolated Sequence) siRNA ... quantitative approach for evaluation of a potential ... an efficient target for RNA interference (RNAi). ... not perfect, leaving the probability of selected ...
Biology Products: